Oppenheimer analyst Leah R. Cann initiated coverage on shares of MEI Pharma Inc (NASDAQ:MEIP) with an Outperform rating and $6.
MEI Pharma, Inc. (NASDAQ:MEIP) and Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, announced final results from a Phase …
MEI Pharma Inc (NASDAQ:MEIP), an oncology company focused on the clinical development of novel therapies for cancer, today reported results for its fiscal year …
MEI Pharma Inc (NASDAQ:MEIP), an oncology company focused on the clinical development of novel therapies for cancer and Helsinn, a Swiss pharmaceutical group focused on …
MEI Pharma Inc (NASDAQ:MEIP) just received Breakthrough Therapy Designation for its key pipeline drug pracinostat, anti-tumor molecule inhibitor that combined with azacitidine treats …
MEI Pharma Inc (NASDAQ:MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced new clinical data from a …
When investing in biotech companies, I try to find undervalued companies with low-risk upcoming catalysts. For example, several months ago when Medivation (NASDAQ:MDVN) …
MEI Pharma Inc (NASDAQ:MEIP), an oncology company focused on the clinical development of novel therapies for cancer, today announced the appointment of Christine White, …
MEI Pharma Inc (NASDAQ:MEIP), an oncology company focused on the clinical development of novel therapies for cancer, today announced positive results from a …
I wrote an article last week detailing why investors should buy MEI Pharma Inc (NASDAQ:MEIP) before the American Society of Hematology (ASH) meeting on Decemeber …